

IN THE SPECIFICATION

Please replace the last paragraph on page 14 with the following:

**Cytotoxicity:** Compounds IXa and IXc were evaluated for *in vitro* against sixty human tumor cells derived from nine cancer types (leukemia, non-small-cell lung, colon, CNS, melanoma, ovarian, prostate, and breast cancer). For each compound, dose response curves against each cell line were measured at a minimum of five concentrations at 10 fold dilutions. A protocol of 48 h continuous drug exposure was used at a sulforhodamine B (SRB) protein assay was used to estimate cell viability or growth. The concentration causing 50% cell growth inhibition (GI50), total cell growth inhibition (TGI, 0% growth) and 50% cell death (LC50, -50% growth) compared with the control was calculated. The mean graph midpoint values of  $\log_{10}$  TGI and  $\log_{10}$  LC50 as well as  $\log_{10}$  GI50 for IXa and IXc are listed in Table 1. As demonstrated by mean graph pattern (Table 4), compound IXc exhibits an interesting profile of activity and selectivity for various cell lines. The mean graph mid point of  $\log_{10}$  TGI and  $\log_{10}$  LC50 showed similar pattern to the  $\log_{10}$  GI50 mean graph mid points.

Please replace Table 4 on page 16 and 17 with the attached Table 4.

MEAN GRAPH TABLE 4



Detailed description of Figure 2: This is a bar chart comparing Log<sub>10</sub>(G1S0) on the y-axis against Log<sub>10</sub>(LCSA) on the x-axis for 30 different cancer cell lines. The y-axis scale is from -3 to 3, and the x-axis scale is also from -3 to 3. Each cell line has a black bar indicating its G1S0 value and a vertical error bar indicating its LCSA value. A horizontal dashed line is drawn at Log<sub>10</sub>(LCSA) = 0. Most cell lines show Log<sub>10</sub>(LCSA) values between -1 and 1, while Log<sub>10</sub>(G1S0) values are generally between -2 and 2.

Panel/Cell Line	Log <sub>10</sub> (G1S0)	Log <sub>10</sub> (LCSA)
Leukemia		
CCRF-CEM	< -4.00	-7.65
K-51	< -4.00	-6.46
MOLT-4	< -4.00	-7.18
RPMI-8226	< -4.00	-7.41
SR	< -4.00	< -4.00
Non-Small Cell Lung Cancer		
A431/ATCC	-4.86	-4.00
BTKX	-5.77	-4.20
HOP-62	< -4.00	-5.26
NCI-H226	< -4.00	-6.63
NCI-H23	< -4.00	-6.13
NCI-H224M	< -4.00	-7.04
NCI-H460	< -4.00	-5.84
NCI-H322	-4.98	-4.72
Colo Cancer		
COLO-205	-6.77	-6.55
HCT-116	-7.04	-6.33
HCT-115	-6.07	-6.73
HT29	-6.16	-5.87
KM12	-4.90	-4.46
SW-620	-4.56	-4.63
CNS Cancer		
SP-293	< -4.00	-6.06
SP-293	< -4.00	-4.35
SVB-19	-4.42	-6.35
U251	-1.86	> -4.00
Melanoma		
LOX-GATT	< -4.00	-6.64
M14	-6.98	-6.58
SK-MEL-2	-7.79	-6.89
SK-MEL-24	-4.49	-6.41
SK-MEL-3	-4.37	-5.07
UACC-32	-6.63	-6.33
Ovarian Cancer		
IGROV1	-4.79	-6.43
OVCAR-3	-7.87	-6.70
OVCAR-4	-7.63	-6.90
OVCAR-5	-5.63	-6.69
OVCAR-35	-7.27	-6.13
OVCAR-4	-4.59	-6.47
SK-OV-3	-4.22	-4.06
Renal Cancer		
786-O	< -4.00	-6.50
ACHN	-7.54	-6.50
Caki-1	< -4.00	-6.32
RXP-193	-7.12	-4.81
SNU-2C	-6.74	-4.59
TK-10	-4.80	-4.31
UO-31	-4.52	-6.44
Promote Cancer		
PC-3	-4.96	-5.80
DU-145	-4.60	-6.34
Breast Cancer		
MDCF7	< -4.00	-6.17
NCIADR-2B5	-4.41	-6.84
MDA-MB-231/ATCC	-4.61	-5.20
IS 39T	-6.91	-6.16
MDA-MB-435	-7.08	-6.39
BT-549	-6.63	-6.63
T-470	-6.55	-6.19
MG-MID	.74	-4.30
Dalis	.86	-6.27
Range	.37	1.77
		4.00

MEAN GRAPH TABLE 4

